March 14, 2013 - Medgenics, Inc. (NASDAQ:GNMC) has filed a financial statement reporting Liabilities of $12,195,000 USD. Previously, on March 14, 2013, Medgenics, Inc. reported Liabilities of $4,608,000 USD. This represents a change of 164.65% in Liabilities.

Period EndPeriodValue
2010-12-31 2010-Q4 12,195,000
2011-06-30 2011-Q2 4,608,000
2011-09-30 2011-Q3 5,022,000
2011-12-31 2011-Q4 3,865,000
2012-06-30 2012-Q2 7,660,000
2012-12-31 2012-Q4 5,773,000
2014-12-31 2014-Q4 4,618,000
2015-12-31 2015-Q4 3,908,000
2016-12-31 2016-Q4 5,583,000
2018-03-31 2018-Q1 4,739,000
2017-12-31 2017-Q4 4,140,000
2012-03-31 2012-Q1 4,666,000
2016-03-31 2016-Q1 3,555,000
2015-09-30 2015-Q3 10,409,000
2015-06-30 2015-Q2 3,766,000
2015-03-31 2015-Q1 3,513,000
2014-09-30 2014-Q3 3,561,000
2014-06-30 2014-Q2 4,352,000
2014-03-31 2014-Q1 4,657,000
2013-09-30 2013-Q3 6,372,000
2013-06-30 2013-Q2 4,426,000
2013-03-31 2013-Q1 5,115,000
2012-09-30 2012-Q3 7,122,000
2016-06-30 2016-Q2 3,927,000
2013-12-31 2013-Q4 4,664,000
2016-09-30 2016-Q3 5,496,000
2017-03-31 2017-Q1 5,450,000
2017-06-30 2017-Q2 4,917,000
2017-09-30 2017-Q3 6,857,000
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther FinancialExpenses GeneralAndAdministrativeExpense IncomeTaxExpenseBenefit IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets OtherFinanceExpense OtherNonoperatingExpense OtherResearchAndDevelopmentExpense PrepaidExpenseAndOtherAssetsCurrent ResearchAndDevelopmentExpense ResearchAndDevelopmentExpensesGross

Related News Stories

Aevi Genomic Medicine: Try Subgroups Until It Works?

2018-05-20 seekingalpha
Aevi's current strategy has a reasonable chance of success, but the stock has several red flags and remains highly speculative. (20-0)

Aevi Genomic (GNMX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow

2018-03-29 seekingalpha
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with this event. (16-1)